Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: Les H who wrote (171471)	6/10/2002 9:37:27 AM
From: Les H	Read Replies (3) \| Respond to of 436258

Ernst & Young prepares a "survival index" to show how much cash public biotech companies have in their coffers. In 1999, as a financing drought was ending, only 25 percent of the companies examined had five or more years of cash. That figure now stands at 43 percent, close to a record. On the other hand, fully 34 percent of companies have less than two years of cash on hand, and it is clear that many of them will have difficulty raising more in the present climate. If a new financing window doesn't open soon, and if the past is any guide, some of these companies will have no choice but to embrace "toxic" financing deals that lure new money by sharply undermining the interests of existing shareholders. washingtonpost.com